To evaluate safety and efficacy of therapeutic vaccination with chimpanzee adenovirus (ChAdV)- and poxvirus modified vaccinia Ankara (MVA)-vectored vaccines in a sequential regimen with the Toll-like Receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1.

The reasons this study is being conducted are: • To see if human immunodeficiency virus (HIV) antiretroviral medicines that you are taking continue to work well in transgender women and other individuals identifying as female or transfeminine but with male sex assigned at birth (referred to as transgender women throughout this form) when taken with feminizing hormone therapy (FHT), also known in this study as estradiol; and • To see if estradiol levels in blood vary between boosted and un-boosted HIV medicines when transgender women are taking different doses of FHT.

The purpose of this study is to: • Observe how LEN moves throughout the body in US cisgender women • Evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women • valuate the acceptability of LEN injections and oral F/TDF in US cisgender women Cisgender means whatever gender you are now is the same as the sex that you were assigned at birth.

The purpose of this expanded access IND (compassionate use) program is to provide tecovirimat for treatment or prevention of non-variola orthopoxvirus infections (e.g., vaccinia, monkeypox, cowpox or other human virus infection identified as an orthopoxvirus) and secondary treatment of complications from replication-competent vaccinia vaccine in adults and children.

The purpose of this study is to tell if a disinfectant wipe with a blue dye additive increases the thoroughness of cleaning and disinfection and reduces contamination.

The purpose of this research study is to determine how bictegravir (BIC), also known as GS 9883, and lenacapavir (LEN) affect the HIV-1 infection in your body and compare it with current standard treatment regimens.

The goal of this study is to develop new ways of figuring out which children with acute respiratory illnesses (like cough, cold, or flu) would benefit from antibiotic treatment. To do this, we will evaluate different combinations of vital signs, symptoms, results from tests for infections that cause respiratory illness, and measurement of the body's immune response to see which ones best predict the presence of infection that requires antibiotic treatment.

To find out if certain study treatments (study interventions) can help treat exercise intolerance and post-exertional malaise that started or got worse after a COVID-19 infection and have lasted for at least 3 months

The goal of the ABACUS-HIV Study is to learn about things that make it easier or more difficult for people with HIV to take their cholesterol medication consistently. WHAT WILL YOU BE ASKED TO DO? Be interviewed for 60-75 minutes in clinic or by phone; All your responses will be confidential; Participants will be compensated $50. WHO CAN JOIN? People living with HIV; At least 18 years old; Prescribed a cholesterol medication called a statin; Can speak English; Have agreed to be in the HIV clinic database at UNC. Patients interested in participating should contact the study team at (919) 843-2532.

This study is being done by the HIV Prevention Trials Network (HPTN). It will compare the safety and acceptability of a rectal douche containing tenofovir to a pill that prevents HIV.